| Project/Area Number |
26461954
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Yokohama City University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
宮城 洋平 地方独立行政法人神奈川県立病院機構神奈川県立がんセンター(臨床研究所), がん分子病態学部, 総括部長 (00254194)
山中 歩 横浜市立大学, 附属病院, 指導診療医 (00728339)
益田 宗孝 横浜市立大学, 医学研究科, 教授 (10190365)
益戸 功彦 横浜市立大学, 附属市民総合医療センター, 助教 (10404972)
利野 靖 横浜市立大学, 附属病院, 准教授 (50254206)
吉田 明 地方独立行政法人神奈川県立病院機構神奈川県立がんセンター(臨床研究所), 乳腺内分泌外科, 部長 (70182748)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 甲状腺未分化癌 / ヒストン修飾 / EZH2 / 効果予測因子 |
|---|
| Outline of Final Research Achievements |
The purpose of this study is to establish predictive factors of effectiveness of paclitaxel in thyroid cancer and to establish prognostic and therapeutic targets in the epigenetic field. Unfortunately, we could not find predictive factors for paclitaxel in anaplastic thyroid cancer, but the histone modifying enzyme EZH2 overexpression may be associated with the malignancy of thyroid cancer and the expression of Ki67. It turned out that EZH2 is an independent prognostic factor as well as distant metastasis in poorly differentiated thyroid cancer. Currently, we are aiming to establish a new therapy targeting EZH2.
|
